|
1
|
Nargund VH, Tanabalan CK and Kabir MN:
Management of non-muscle-invasive (superficial) bladder cancer.
Semin Oncol. 39:559–572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Al Hussain TO and Akhtar M: Molecular
basis of urinary bladder cancer. Adv Anat Pathol. 20:53–60. 2013.
View Article : Google Scholar
|
|
3
|
May M, Helke C, Nitzke T, Vogler H and
Hoschke B: Survival rates after radical cystectomy according to
tumor stage of bladder carcinoma at first presentation. Urol Int.
72:103–111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Günthert U, Hofmann M, Rudy W, Reber S,
Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P:
A new variant of glycoprotein CD44 confers metastatic potential to
rat carcinoma cells. Cell. 65:13–24. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagano O and Saya H: Mechanism and
biological significance of CD44 cleavage. Cancer Sci. 95:930–935.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ponta H, Sherman L and Herrlich PA: CD44:
From adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kimura Y, Goi T, Nakazawa T, Hirono Y,
Katayama K, Urano T and Yamaguchi A: CD44variant exon 9 plays an
important role in colon cancer initiating cells. Oncotarget.
4:785–791. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ishimoto T, Nagano O, Yae T, Tamada M,
Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al:
CD44 variant regulates redox status in cancer cells by stabilizing
the xCT subunit of system xc(-) and thereby promotes tumor growth.
Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong RL, Pu YS, Hsieh TS, Chu JS and Lee
WJ: Expressions of E-cadherin and exon v6-containing isoforms of
CD44 and their prognostic values in human transitional cell
carcinoma. J Urol. 153:2025–2028. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lipponen P, Aaltoma S, Kosma VM, Ala-Opas
M and Eskelinen M: Expression of CD44 standard and variant-v6
proteins in transitional cell bladder tumours and their relation to
prognosis during a long-term follow-up. J Pathol. 186:157–164.
1998. View Article : Google Scholar
|
|
11
|
Hirata K, Suzuki H, Imaeda H, Matsuzaki J,
Tsugawa H, Nagano O, Asakura K, Saya H and Hibi T: CD44 variant 9
expression in primary early gastric cancer as a predictive marker
for recurrence. Br J Cancer. 109:379–386. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamaguchi A, Urano T, Goi T, Saito M,
Takeuchi K, Hirose K, Nakagawara G, Shiku H and Furukawa K:
Expression of a CD44 variant containing exons 8 to 10 is a useful
independent factor for the prediction of prognosis in colorectal
cancer patients. J Clin Oncol. 14:1122–1127. 1996.PubMed/NCBI
|
|
13
|
Choi W, Porten S, Kim S, Willis D, Plimack
ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al:
Identification of distinct basal and luminal subtypes of
muscle-invasive bladder cancer with different sensitivities to
frontline chemotherapy. Cancer Cell. 25:152–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ishibashi H, Suzuki T, Suzuki S, Moriya T,
Kaneko C, Takizawa T, Sunamori M, Handa M, Kondo T and Sasano H:
Sex steroid hormone receptors in human thymoma. J Clin Endocrinol
Metab. 88:2309–2317. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of
survival for first-line chemotherapy plus cetuximab in patients
with advanced non-small-cell lung cancer: Analysis of data from the
phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar
|
|
16
|
Subik K, Lee JF, Baxter L, Strzepek T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et
al: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and
AR by immunohistochemical analysis in breast cancer cell lines.
Breast Cancer (Auckl). 4:35–41. 2010.
|
|
17
|
Miyake H, Eto H, Arakawa S, Kamidono S and
Hara I: Over expression of CD44V8-10 in urinary exfoliated cells as
an independent prognostic predictor in patients with urothelial
cancer. J Urol. 167:1282–1287. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Muramaki M, Miyake H, Kamidono S and Hara
I: Over expression of CD44V8-10 in human bladder cancer cells
decreases their interaction with hyaluronic acid and potentiates
their malignant progression. J Urol. 171:426–430. 2004. View Article : Google Scholar
|
|
19
|
Damrauer JS, Hoadley KA, Chism DD, Fan C,
Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, et
al: Intrinsic subtypes of high-grade bladder cancer reflect the
hallmarks of breast cancer biology. Proc Natl Acad Sci USA.
111:3110–3115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McConkey DJ, Choi W and Dinney CP: New
insights into subtypes of invasive bladder cancer: Considerations
of the clinician. Eur Urol. 66:609–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshida GJ and Saya H: Inversed
relationship between CD44 variant and c-Myc due to oxidative
stress-induced canonical Wnt activation. Biochem Biophys Res
Commun. 443:622–627. 2014. View Article : Google Scholar
|
|
22
|
Yoshikawa M, Tsuchihashi K, Ishimoto T,
Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K,
Kawashiri S, et al: xCT inhibition depletes CD44v-expressing tumor
cells that are resistant to EGFR-targeted therapy in head and neck
squamous cell carcinoma. Cancer Res. 73:1855–1866. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsugawa H, Suzuki H, Saya H, Hatakeyama M,
Hirayama T, Hirata K, Nagano O, Matsuzaki J and Hibi T: Reactive
oxygen species-induced autophagic degradation of Helicobacter
pylori CagA is specifically suppressed in cancer stem-like cells.
Cell Host Microbe. 12:764–777. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yae T, Tsuchihashi K, Ishimoto T, Motohara
T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H,
et al: Alternative splicing of CD44 mRNA by ESRP1 enhances lung
colonization of metastatic cancer cell. Nat Commun. 3:8832012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshida GJ and Saya H: The novel
anti-tumor therapy targeting the ʻfunctional' cancer stem cell
markers. Clin Exp Pharmacol. 4:1472014.
|
